-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2019-10-16
Values as of: 2019-10-16
The investment seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the Dow Jones U.S. Health CareSM Index. The fund invests in derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times the inverse (-2x) of the daily return of the index. The index measures the performance of the healthcare sector of the U.S. equity market. Component companies include, among others, health care providers, biotechnology companies, medical supplies, advanced medical devices and pharmaceuticals. The fund is non-diversified.
Company Website : www.proshares.com
Currency: USD
Country : USA
Inception Date: 22/10/2014
Primary Benchmark: MSCI EM NR CAD
Primary Index: MSCI EM GR CAD
Gross Expense Ratio: NA%
Management Expense Ratio: 0.77 %
N/A
N/A
Symbol | Company Name | Allocation |
---|---|---|
IYH | iShares U.S. Healthcare ETF | 10.32 % |
N/A
N/A
Symbol | Name | Mer | Price(Change) | Market Cap |
---|---|---|---|---|
SOJE | SOJE | 0.00 % |
+0.20 (+1.06%) |
USD 65.72B |
JEPI | JPMorgan Equity Premium Income.. | 0.00 % |
+0.47 (+0.85%) |
USD 32.43B |
DTB | DTB | 0.00 % |
+0.30 (+1.58%) |
USD 26.58B |
DFAC | Dimensional U.S. Core Equity 2.. | 0.00 % |
+0.28 (+0.93%) |
USD 26.00B |
GBTC | Grayscale Bitcoin Trust (BTC) | 0.00 % |
+1.95 (+3.40%) |
USD 23.75B |
JPST | JPMorgan Ultra-Short Income ET.. | 0.00 % |
+0.02 (+0.04%) |
USD 22.73B |
SGOV | iShares® 0-3 Month Treasury B.. | 0.00 % |
+0.01 (+0.01%) |
USD 19.79B |
AVUV | Avantis® U.S. Small Cap Value.. | 0.00 % |
+0.82 (+0.93%) |
USD 10.49B |
DFUV | Dimensional US Marketwide Valu.. | 0.00 % |
+0.32 (+0.82%) |
USD 10.15B |
DFAT | Dimensional U.S. Targeted Valu.. | 0.00 % |
+0.59 (+1.16%) |
USD 9.40B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
RLD:CA | 0.00 % | 0.61 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Others) | Market Performance vs. Exchange (NYSE Arca) | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -15.05% | 6% | D- | 12% | F | ||
Dividend Return | 0.95% | 29% | F | 19% | F | ||
Total Return | -14.09% | 6% | D- | 12% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -2.68% | 30% | F | 39% | F | ||
Dividend Return | 1.33% | 34% | F | 24% | F | ||
Total Return | -1.35% | 28% | F | 36% | F | ||
Trailing 5 Years | |||||||
Capital Gain | -72.92% | 5% | F | 7% | C- | ||
Dividend Return | 0.38% | 4% | F | 2% | F | ||
Total Return | -72.54% | 4% | F | 6% | D- | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -18.41% | 3% | F | 5% | F | ||
Dividend Return | -18.30% | 3% | F | 4% | F | ||
Total Return | 0.11% | 5% | F | 3% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 11.20% | 46% | F | 67% | D+ | ||
Risk Adjusted Return | -163.49% | 1% | F | 1% | F | ||
Market Capitalization | 2.85M | 4% | F | 2% | F |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.